What is Clover Biopharmaceuticals?
Clover Biopharmaceuticals is a research-driven biotechnology firm headquartered in Chengdu, Sichuan, China. The company specializes in the discovery, development, and commercialization of innovative biologic therapies. Its core mission revolves around addressing significant unmet medical needs, particularly within the complex domains of oncology and autoimmune disorders. By integrating advanced clinical research with a global operational footprint, Clover Biopharmaceuticals maintains a competitive edge in the rapidly evolving biopharma landscape, positioning itself as a key player in the development of next-generation medical interventions.
How much funding has Clover Biopharmaceuticals raised?
Clover Biopharmaceuticals has raised a total of $636.3M across 7 funding rounds:
Series A
$9.5M
Series B
$43M
Other Financing Round
$24M
Grant
$66M
Series C
$230M
Stock Offering
$260.2M
Stock/Share Issuance
$3.6M
Series A (2017): $9.5M, investors not publicly disclosed
Series B (2019): $43M led by Jinlong Group, Sichuan Health Care Industry Fund, Beijing Zhongguancun VC, Delos Capital, Lapam Capital, and Betta Capital
Other Financing Round (2020): $24M supported by GL Ventures LLC
Grant (2020): $66M featuring Coalition for Epidemic Preparedness Innovations
Series C (2021): $230M backed by Temasek and GL Ventures
Stock Issuance/Offering (2021): $260.2M, investors not publicly disclosed
Stock/Share Issuance (2026): $3.6M, investors not publicly disclosed
Key Investors in Clover Biopharmaceuticals
Temasek
Founded in 1974, Temasek is a global investment company headquartered in Singapore. We are a generational investor, seeking to make a difference always with tomorrow in mind.
Delos Capital
Delos Capital is a private equity firm based in New York City that specializes in private investment and financial advisory services, focusing on complex transactions and strategic alignment.
Coalition for Epidemic Preparedness Innovations
An innovative global partnership working to accelerate the development of vaccines against emerging infectious diseases and enable equitable access to these vaccines for people during outbreaks.
What's next for Clover Biopharmaceuticals?
Looking ahead, the strategic deployment of the $3.6M capital will likely focus on the expansion of clinical trial programs and the enhancement of manufacturing capabilities to support late-stage development. Given the company's history of securing major enterprise-level funding, the current roadmap suggests a pivot toward global market penetration and the strengthening of its intellectual property portfolio. Investors and industry analysts will be closely monitoring the firm's progress in navigating regulatory pathways and achieving key clinical milestones, which remain essential for long-term value creation in the high-stakes biotechnology market.
See full Clover Biopharmaceuticals company page
